<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159826">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01977794</url>
  </required_header>
  <id_info>
    <org_study_id>200006-524</org_study_id>
    <nct_id>NCT01977794</nct_id>
  </id_info>
  <brief_title>Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension</brief_title>
  <official_title>A Randomized, Comparative Trial of Concor AM, a Fixed Dose Combination of Bisoprolol and Amlodipine, on the Treatment of Essential Hypertensive Patients Whose Blood Pressure is Not Well Controlled by Monotherapy of Bisoprolol 5mg or Amlodipine 5mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Guatemala: Ministry of Public Health and Social Assistance</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, comparative  Phase 3 trial to investigate the efficacy of fixed dose
      combination (FDC) of bisoprolol and amlodipine in hypertensive subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean reduction of  systolic blood pressure (SBP) after 18 weeks of treatment from Baseline (latest SBP before study treatment)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline (latest diastolic blood pressure [DBP] before study treatment) in DBP after 18 weeks of treatment</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with controlled blood pressure under different dosages of after study treatment</measure>
    <time_frame>Baseline up to Day 127 (end of trial)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline (latest heart rate [HR] before study treatment) in HR after 18 weeks treatment</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs)</measure>
    <time_frame>Baseline up to Day 127 (end of trial)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Bisoprolol sub-group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received monotherapy of bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol sub-group A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bisorprolol sub-group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received monotherapy of bisoprolol 5 mg before trial inclusion will be randomized to bisoprolol sub-group B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine sub-group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received monotherapy of amlodipine 5 mg before trial inclusion will be randomized to bisoprolol sub-group A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine sub-group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received monotherapy of amlodipine 5 mg before trial inclusion will be randomized to bisoprolol sub-group B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol/Amlodipine (Bisoprolol sub-group A)</intervention_name>
    <description>Bisoprolol/Amlodipine fixed dose combination (FDC) tablet will be orally administered as an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43 (Visit 2), the same dose will continue for next 6 weeks.  If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 5mg/10mg after Visit 2 and are controlled at visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.</description>
    <arm_group_label>Bisoprolol sub-group A</arm_group_label>
    <other_name>Concor AM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol/Amlodipine (Bisoprolol sub-group B)</intervention_name>
    <description>Bisoprolol/Amlodipine FDC tablet will be orally administered as an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43 (Visit 2), the same dose will continue for next 6 weeks.  If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 10mg/5mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 10mg/5mg after Visit 2 and are controlled at visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.</description>
    <arm_group_label>Bisorprolol sub-group B</arm_group_label>
    <other_name>Concor AM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol/Amlodipine (Amlodipine sub-group A)</intervention_name>
    <description>Bisoprolol/Amlodipine FDC tablet will be orally administered as an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43 (Visit 2), the same dose will continue for next 6 weeks. If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 5mg/10mg and are controlled at Visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.</description>
    <arm_group_label>Amlodipine sub-group A</arm_group_label>
    <other_name>Concor AM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol/Amlodipine (Amlodipine sub-group B)</intervention_name>
    <description>Bisoprolol/Amlodipine FDC tablet will be orally administered as an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43(Visit 2), the same dose will continue for next 6 weeks. If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 10mg/5mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 10mg/5mg and are controlled at Visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.</description>
    <arm_group_label>Amlodipine sub-group B</arm_group_label>
    <other_name>Concor AM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Essential hypertension not controlled at 5 mg bisoprolol or 5 mg amlodipine at least
             4 weeks (definition of not controlled: SBP greater than or equal to (&gt;=) 140
             millimeter of mercury (mmHg) with or without DBP &gt;= 90 mmHg)

          -  Male or female subjects &gt;=18 years of age, without limitation on race

          -  Medically accepted effective contraception if procreative potential exists
             (applicable for both male and female subjects until at least 90 days after the last
             dose of trial treatment)

          -  Subjects who have signed the informed consent form before any trial related
             assessment

        Exclusion Criteria:

          -  General contraindications of beta-blockers and/or calcium channel blockers

               -  Previous and concurrent acute heart failure or during episodes of heart failure
                  decompensation requiring intravenous inotropic therapy

               -  Concurrent cardiogenic shock

               -  Previous and concurrent second or third degree atrioventricular (AV) block
                  (without a pacemaker)

               -  Previous and concurrent sick sinus syndrome

               -  Previous and concurrent sinoatrial block

               -  Concurrent symptomatic bradycardia

               -  Concurrent symptomatic hypotension

               -  Previous and concurrent severe bronchial asthma or chronic obstructive pulmonary
                  diseases

               -  Previous and concurrent severe peripheral arterial occlusive diseases and
                  Raynaud's syndrome

               -  Untreated pheochromocytoma

               -  Concurrent metabolic acidosis

               -  Known hypersensitivity to bisoprolol, amlodipine, dihydropyridine derivates or
                  to any of the excipients

          -  Seated pulse rate less than 60 beats per minute (bpm) at screening

          -  Any other anti-hypertensive drugs (other than bisoprolol and amlodipine) are used
             within 4 weeks prior to the screening visit

          -  Use of any enzyme-modifying drugs acting on cytochrome P450 (CYP) 3A4 enzymes via
             inhibition (such as ketoconazole, itraconazole, ritonavir) or induction (such as
             rifampicin or hypericum perforatum) within 28 days before Day 1 of the trial

          -  Other significant disease that in the Investigator's opinion that would exclude the
             subject from the trial, such as uncontrolled diabetes mellitus, severe liver and/or
             kidney dysfunction, decompensated cardiac failure

          -  Any other condition or therapy which in the Investigator's opinion would pose a risk
             to the subject or interfere with the trial objectives

          -  Concurrent alcohol and/or drug abuse

          -  Known hypersensitivity to the trial treatments

          -  Pregnancy and lactation period. All female subjects with reproductive potential must
             have a negative pregnancy serum test within the 7 days prior to enrollment

          -  Known lack of subject compliance

          -  Legal incapacity or limited legal capacity

          -  Participation in another clinical trial within the previous 30 days

          -  Persons directly involved in the execution of the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regional medical director LATAM</last_name>
    <role>Study Director</role>
    <affiliation>Merck S.A., Brazil, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Please contact the Merck KGaA Communication Center located in</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+49 6151 72 5200</phone>
      <email>service@merckgroup.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 31, 2013</lastchanged_date>
  <firstreceived_date>October 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bisoprolol</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>Fixed dose combination (FDC)</keyword>
  <keyword>Systolic Blood Pressure (SBP)</keyword>
  <keyword>Diastolic Blood Pressure (DBP)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
